Adults whose thymus glands show less age-related deterioration on chest CT scans face lower risks of death, cancer, and cardiovascular disease, according to two studies published in Nature in 2026. The findings draw on deep-learning analysis of imaging from the National Lung Screening Trial and the Framingham Heart Study, with NLST follow-up extending a median of roughly 12 years. Taken alongside earlier clinical evidence that removing the thymus during heart surgery raises the risk of death and disease, the research builds a case that this small, often-overlooked organ remains a measurable marker of immune resilience well into old age.
CT-derived thymic scores and what they reveal about aging
The thymus sits behind the breastbone and produces T cells, the white blood cells that coordinate immune responses against infections and abnormal cell growth. After puberty, the gland gradually shrinks and fills with fatty tissue. For decades, most clinicians treated this involution as irrelevant. The new research challenges that assumption by quantifying how much functional thymic tissue remains on scans originally taken for other purposes and then tracking what happened to those patients over the following years.
A deep-learning model generated a CT-based thymic health score by distinguishing residual soft tissue from fat within the gland. In the Nature analysis, this imaging-derived metric was applied to two large prospective cohorts and showed that individuals with lower scores had higher all-cause mortality and higher incidence of both cancer and cardiovascular disease. The algorithm was trained on standard chest CTs, meaning it could, in theory, be layered onto scans that millions of people already receive for lung cancer screening or cardiac workups without any additional imaging or radiation exposure.
The NLST, a randomized trial run by the National Cancer Institute, originally enrolled participants to compare low-dose CT with standard chest X-ray for lung cancer detection. Deaths and causes of death were systematically captured using ICD-10 codes from death certificates, with details documented in the trial’s mortality ascertainment procedures. That robust endpoint allowed researchers to test how well the thymic health score predicted long-term survival beyond traditional risk factors such as age, smoking history, and baseline comorbidities. The Framingham Heart Study CT cohorts added a second independent population with established thoracic and mediastinal phenotyping, including prior characterization of the thymus, strengthening the generalizability of the findings.
A companion Nature paper extended the concept into oncology, linking CT-measured thymic health to T-cell receptor diversity and survival outcomes across multiple cancer types. Participants whose scans showed more preserved thymic tissue tended to have broader repertoires of T-cell receptors, suggesting that a healthier thymus continues to export new T cells capable of recognizing diverse antigens. That connection offers a biological explanation for why a healthier thymus might matter: greater T-cell diversity means the immune system can recognize and attack a wider range of threats, from viral infections to tumor cells, potentially improving responses to standard therapies and immunotherapies.
Thymectomy evidence strengthens the biological argument
The CT-based findings do not stand alone. A separate line of evidence comes from patients who had their thymus removed, or thymectomy, during cardiothoracic surgery. In an observational study reported in the New England Journal of Medicine, adults who underwent thymectomy showed higher risks of death and major cardiovascular events compared with matched controls whose thymus was left intact. The comparison involved surgical patients matched on key clinical characteristics, including age, sex, type of procedure, and baseline health conditions, helping to isolate the thymus itself as a variable rather than a simple proxy for overall frailty.
The thymectomy data and the CT scoring data converge on the same conclusion from opposite directions. One asks what happens when the thymus is physically removed; the other asks what happens as it naturally decays at different rates across individuals. Both point toward the same outcome: less thymic function correlates with worse health trajectories. Commentary accompanying the Nature papers described the approach as “individualized thymic decay quantified from routine CT,” framing it as a new window into a process that previously required specialized blood tests to assess, such as T-cell receptor sequencing or measurements of recent thymic emigrants.
For patients over 60, the practical question is whether a thymic health score derived from a scan they may already be getting could outperform simpler predictors of decline. Chronological age is a blunt instrument. Existing comorbidity indices tally up diagnosed conditions but say little about the immune system’s remaining capacity. A thymic score, by contrast, would capture a biological process tied directly to immune competence. Whether it can predict specific outcomes like frailty, infection-related hospitalizations, or poor vaccine responses more accurately than those conventional measures has not yet been tested in a head-to-head comparison, but the mortality and disease associations reported so far suggest the signal is strong enough to warrant that trial.
Open questions about thymic health as a clinical tool
Several gaps separate these findings from routine clinical use. The deep-learning algorithm’s exact performance metrics, including calibration across scanners and institutions, have not been publicly released in a format that independent teams can fully evaluate. Without those details, other hospitals and imaging centers cannot yet replicate the scoring on their own patient populations or be sure how well the score will generalize to different demographics and imaging protocols.
The thymectomy cohort, while carefully matched, carries an inherent limitation: surgeons removed the thymus for specific clinical reasons, and the underlying conditions that led to surgery may themselves influence long-term outcomes. The published analysis accounted for this through its matching strategy and statistical adjustments, but detailed thymic pathology reports and surgical indications remain summarized rather than fully transparent in the available record. Residual confounding cannot be entirely ruled out, particularly around unmeasured factors such as subtle differences in operative complexity or postoperative care.
Another major uncertainty is how CT-derived thymic scores relate to contemporaneous blood-based markers of immune function. No study has yet measured, within the same group of NLST or Framingham participants, how imaging scores correlate with T-cell receptor excision circles, direct T-cell receptor sequencing, or functional assays of T-cell responses. Establishing that link would confirm that the imaging score truly reflects ongoing thymic output and immune repertoire diversity rather than simply the amount of soft tissue in the anterior mediastinum.
Intervention studies are also missing. At present, a low thymic health score is a risk marker, not a modifiable treatment target. It is unknown whether any intervention-whether lifestyle changes, vaccination strategies tailored to immune age, or experimental thymus-boosting therapies-can meaningfully alter the trajectory captured by the CT score. Without evidence that acting on the metric improves outcomes, clinicians may be hesitant to incorporate it into decision-making beyond research protocols.
There are practical considerations as well. Incorporating automated thymic analysis into radiology workflows would require validated software, clear reporting standards, and guidance on how clinicians should respond to different score ranges. Ethically, any move toward labeling patients as having “accelerated immune aging” based on imaging must be coupled with counseling and, ideally, concrete options for risk reduction to avoid causing anxiety without benefit.
Still, the convergence of large-cohort imaging data and surgical outcomes suggests that the thymus deserves renewed attention in adult medicine. Rather than a vestigial remnant of childhood, it appears to function as a barometer of immune resilience whose decline tracks with vulnerability to cancer, cardiovascular disease, and premature death. As researchers refine CT-based scoring, link it to blood biomarkers, and test interventions in prospective trials, thymic health could evolve from an anatomical curiosity into a clinically useful measure of biological age.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
